Abstract

Abstract Guillain-Barre syndrome (GBS) is a rare acute paralytic polyneuropathy, with an incidence of about 1 in 100,000. It occurs in adults and children. It is an autoimmune disorder of the peripheral nervous system often triggered by acute infections – the most common being gastrointestinal or respiratory – leading to an immune mediated response of producing antibodies to antigens which react with the myelin sheath of the peripheral nerves, resulting in demyelination and/or axonal injury. In severe cases, GBS may lead to respiratory failure, and even death. Current treatment options include treatment with intravenous immunoglobulin and/or plasmapharesis which are aimed at neutralising, and removal of circulating antibodies from the bloodstream respectively, alongside supportive measures to maintain motor function.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.